4-Nov-2024	Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

2-Oct-2024	Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy at the American Society for Radiation Oncology 66th Annual Meeting

23-Sep-2024	Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

12-Sep-2024	Kazia Executes Licensing Agreement with QIMR Berghofer

10-Jul-2024	Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

27-Jun-2024	Kazia Announces Upcoming DIPG Data Presentations at ISPNO And Publication in European Journal of Cancer

2-May-2024	Kazia Reports Successful Stage 1 Completion Of The Evt801 Phase 1 Clinical Trial In Advanced Cancer Patients

21-Mar-2024	Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

14-Mar-2024	Kazia announces presentation of new data at AACR Annual Meeting

21-Feb-2024	Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

19-Jan-2024	Kazia Continues Board Renewal With Two New Appointments

15-Jan-2024	Resignation of Chief Financial Officer; Appointment of Principal Accounting Officer and Principal Financial Officer

2-Dec-2023	Kazia Therapeutics Announces $2 Million Registered Direct Offering

1-Dec-2023	Kazia AGM - Chairman's Address

1-Dec-2023	Kazia 2023 Annual General Meeting R&D and Clinical Overview

1-Dec-2023	Kazia AGM Meeting results

29-Nov-2023	Kazia Announces Non-binding Letter of Intent for the Proposed Granting of Rights to Develop and Commercialize Paxalisib Outside of Oncology

21-Nov-2023	Kazia Provides Overview Of Paxalisib Related Presentations from the Society Of Neuro-oncology 2023 Annual Meeting